Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision, addresses ongoing and future innovations in eye lens technology and instruments for cataract surgery.
Innovations in eye lens technology will continue to focus on improving patient’s functioning, with further progress being made in optimizing the cataract surgery process, said Raj Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson (J&J) Vision.
Transcript
Where do you see eye lens technology going in the next 5 to 10 years?
Certainly continuing to develop technology that continues to improve patient's functioning. We are hoping to continue to be able to provide options that patients can then choose, to minimize their need for glasses after cataract surgery.
We are also continuing to develop the instruments and the technology that's used in cataract surgery. We introduced at J&J Vision this year the VERITAS system, which is the phacoemulsification, or ultrasound system, that actually breaks apart the cataract during surgery.
So, as I was mentioning earlier, during cataract surgery, we make this microscopic incision, and then we use this phacoemulsification equipment, such as VERITAS, to break apart the hard lens. Just like in kidney stones, ultrasound is used to break apart the kidney stone. Then after we've removed all of the cataract, that's when we put the lens implant in place.
As I mentioned earlier, we also have developed and are continuing to develop advances in laser technology that also assist in that cataract surgery process in the operating room.
Drug Interactions With Ibrutinib Common, Linked to Higher Infection Risk in CLL
September 16th 2025Drug interactions with ibrutinib may not shorten survival when managed carefully, though the significant increase in infection-related hospitalizations tied to CYP3A inhibitors signals an urgent need for closer monitoring, dose adjustment, and proactive infection prevention strategies.
Read More
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen